Healthcare Losers: Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), AMN Healthcare Services Inc. (NYSE:AHS), BioLineRx, Ltd. (NASDAQ:BLRX), Synthetic Biologics Inc. (NYSEMKT:SYN), CorMedix, Inc. (NYSEMKT:CRMD)

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) belongs to Healthcare sector. Its weekly performance is -7.44%. On last trading day company shares ended up $21.27. Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) distance from 50-day simple moving average (SMA50) is 1.69%. On 25 June, Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) announced that Rick Shea has advised the Company of his intention to step down as Chief Financial Officer (CFO) once a successor is identified and appointed. Mr. Shea will remain with the Company to assist with the CFO succession and serve in a newly created role of Senior Vice President, Corporate Communications and Operations for a transition period prior to his planned retirement in 2016. Momenta has initiated a CFO search.

AMN Healthcare Services Inc. (NYSE:AHS) shares decreased -5.12% in last trading session and ended the day at $29.82. AHS Gross Margin is 30.60% and its return on assets is 5.60%. AMN Healthcare Services Inc. (NYSE:AHS) quarterly performance is 27.44%. Jeanette Sanchez, Chief Information Officer for AMN Healthcare, Services Inc. (NYSE:AHS) the nation’s leader and innovator in healthcare workforce solutions and staffing services, has been named as one of San Diego’s Top Tech Execs.

On 02 July, BioLineRx, Ltd. (NASDAQ:BLRX) shares decreased -5.66% and was closed at $2.50. BioLineRx, Ltd. (NASDAQ:BLRX) year to date (YTD) performance is 54.32%. BioLineRx Ltd. (NASDAQ: BLRX) announced that it presented positive safety results of its Phase 1/2 study for BL-7010 a novel polymer for the treatment of celiac disease at the 16th International Celiac Disease Symposium (ICDS 2015) took place from June 21-24 in Prague Czech Republic.

Synthetic Biologics Inc. (NYSEMKT:SYN) ended the last trading day at $2.62. Company weekly volatility is calculated as 9.31% and price to cash ratio as 15.98. Synthetic Biologics Inc. (NYSEMKT:SYN) showed a weekly performance of -6.09%. Synthetic Biologics Inc., (NYSEMKT:SYN) reported the initiation of a Phase 2 clinical trial of its proprietary SYN-010 for the treatment of irritable bowel syndrome with constipation (IBS-C).

CorMedix, Inc. (NYSEMKT:CRMD) shares decreased -5.35% in last trading session and ended the day at $3.54. CRMD Gross Margin is -100.00% and its return on assets is -122.70%. CorMedix, Inc. (NYSEMKT:CRMD) quarterly performance is -61.01%. CorMedix Inc. (NYSE MKT: CRMD), announced, the company is on the preliminary list of additions posted June 12 and 19th to join the Russell 3000 Index and Russell Global Index at the conclusion of the reconstitution on June 26th according to Russell Indexes Reconstitution.

Leave a Reply

Your email address will not be published. Required fields are marked *